Can a single Protein's mutations predict esophageal cancer outcomes?
NCT ID NCT07722819
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study examines 300 esophageal cancer tissue and blood samples to classify tumors based on p53 gene mutations, protein expression, and immune response. Researchers will link these molecular subtypes to patient survival and treatment patterns. The goal is to see whether p53 features can help predict outcomes and guide future treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better classification of esophageal cancers and help tailor treatment decisions based on p53 features.
- What could go wrong
- This is an observational, retrospective analysis, not a treatment trial. The findings may not directly change patient care without further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New drug cocktail aims to shrink Hard-to-Treat esophageal tumors
- Smart T-Cell engager aims to outsmart tumors in first human test
- DNA clues may reveal which esophageal cancers will return soon after surgery